Donor T cells for CAR T cell therapy

Tang, Tiffany C. Y.; Xu, Nuo; Nordon, Robert E.; Haber, Michelle; Micklethwaite, Kenneth; Dolnikov, Alla

doi:10.1186/s40364-022-00359-3

Cited by 13 publications

(10 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CAR T-ddBCMA product, utilizing a novel synthetic binding domain, called D-Domain, demonstrated an ORR of 100% (≥VGPR 88%) after a median follow up of approximately 10 months [ 150 ]. Allogenic CAR T-cell products generated from T-cells of healthy donors have also been clinically assessed with promising outcomes and acceptable AE profiles; however, they have not been approved for clinical use yet [ 151 , 152 ]. These might be a good option for patients requiring prompt treatment and who cannot wait for the time-consuming manufacture of autologous CAR T-cells.…”

Section: Available Therapeutic Modalitiesmentioning

confidence: 99%

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Dima

Ullah

Mazzoni

et al. 2023

Cancers

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematologic malignancy in adults worldwide. Over the past few years, major therapeutic advances have improved progression-free and overall survival, as well as quality of life. Despite this recent progress, MM remains incurable in the vast majority of cases. Patients eventually relapse and become refractory to multiple drug classes, making long-term management challenging. In this review, we will focus on the treatment paradigm of relapsed/refractory MM (RRMM) in the era of advanced therapies emphasizing the available novel modalities that have recently been incorporated into routine practice, such as chimeric antigen receptor T-cell therapy, bispecific antibodies, and other promising approaches. We will also discuss major factors that influence the selection of appropriate drug combinations or cellular therapies, such as relapse characteristics, and other disease and patient related parameters. Our goal is to provide insight into the currently available and experimental therapies for RRMM in an effort to guide the therapeutic decision-making process.

show abstract

Section: Available Therapeutic Modalitiesmentioning

confidence: 99%

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Dima

Ullah

Mazzoni

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Off-the-shelf CAR T-cells are newly developed universal allogeneic CAR T-cells where T-cells are collected from healthy donors. This ensures that a good number of healthy T-cells are retrieved and, unlike autologous CAR T-cells, are not affected by chemotherapy or cancer cells [117,118]. It was suggested that CAR T-cells performance could be greatly affected by the quality and quantity of retrieved T-cells [53,119].…”

Section: Future Prospects For Car T-cell Therapy In the Treatment Of Allmentioning

confidence: 99%

“…It allows the patient to have immediate access to the treatment. There is no need to wait for the 3-week interval which is usually required to manufacture personalized autologous CAR T-cells [115,118]. The term (FasTCAR) is gaining popularity and is used to indicate the next-day manufacturing of CAR T-cells using novel manufacturing platforms.…”

Section: Future Prospects For Car T-cell Therapy In the Treatment Of Allmentioning

confidence: 99%

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects

Almaeen,

Abouelkheir

2023

Biomedicines

View full text Add to dashboard Cite

The currently available treatment for acute lymphoblastic leukemia (ALL) is mainly dependent on the combination of chemotherapy, steroids, and allogeneic stem cell transplantation. However, refractoriness and relapse (R/R) after initial complete remission may reach up to 20% in pediatrics. This percentage may even reach 60% in adults. To overcome R/R, a new therapeutic approach was developed using what is called chimeric antigen receptor-modified (CAR) T-cell therapy. The Food and Drug Administration (FDA) in the United States has so far approved four CAR T-cells for the treatment of ALL. Using this new therapeutic strategy has shown a remarkable success in treating R/R ALL. However, the use of CAR T-cells is expensive, has many imitations, and is associated with some adverse effects. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are two common examples of these adverse effects. Moreover, R/R to CAR T-cell therapy can take place during treatment. Continuous development of this therapeutic strategy is ongoing to overcome these limitations and adverse effects. The present article overviews the use of CAR T-cell in the treatment of ALL, summarizing the results of relevant clinical trials and discussing future prospects intended to improve the efficacy of this therapeutic strategy and overcome its limitations.

show abstract

“…Therefore, it has been widely adopted for alloCAR-T cells. Justin Eyquem et al first targeted a CAR to the TRAC locus with CRISPR/Cas9 and enhanced its tumor elimination ability compared to traditional CAR-T [ 143 , 144 ]. Subsequently, Xiaojuan Liu et al verified that CRISPR/Cas9 mediated editing of TRAC and B2M is readily applicable to alloCAR-T cells [ 145 ].…”

Section: Strategies For Enhancing Car-t Cell Function By Genetic Mani...mentioning

confidence: 99%

Strategies to enhance CAR-T persistence

Liu

Huang

et al. 2022

Biomark Res

View full text Add to dashboard Cite

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused modest long-term survival with CAR-T cell alone. One of the main challenges is the limited persistence of CAR-T cells. To further optimize the clinical effects of CAR-T cells, many studies have focused on modifying the CAR structure and regulating CAR-T cell differentiation. In this review, we focus on CAR-T cell persistence and summarize the latest progress and strategies adopted during the in vitro culture stage to optimize CAR-T immunotherapy by improving long-term persistence. Such strategies include choosing a suitable cell source, improving culture conditions, combining CAR-T cells with conventional drugs, and applying genetic manipulations, all of which may improve the survival of patients with hematologic malignancies by reducing the probability of recurrence after CAR-T cell infusion and provide clues for solid tumor CAR-T cell therapy development.

show abstract

Donor T cells for CAR T cell therapy

Cited by 13 publications

References 123 publications

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

Management of Relapsed–Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice

CAR T-Cells in Acute Lymphoblastic Leukemia: Current Status and Future Prospects

Strategies to enhance CAR-T persistence

Contact Info

Product

Resources

About